Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

NCT07680933 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG: Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT

Sponsor

The Affiliated Hospital of Xuzhou Medical University